PriceTargets.com logo

NASDAQ:FGEN - FibroGen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $45.83
  • Forecasted Upside: 117.01 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$21.12 As of 04/22/2021 01:00 AM ET
▲ +0.06 (0.28%)
1 month | 3 months | 12 months
Get New FibroGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FGEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$45.83
▲ +117.01% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for FibroGen in the last 3 months. The average price target is $45.83, with a high forecast of $58.00 and a low forecast of $29.00. The average price target represents a 117.01% upside from the last price of $21.12.
Hold
The current consensus among 8 polled investment analysts is to hold stock in FibroGen. This rating has held steady since October 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralN/A
i
4/13/2021HC WainwrightReiterated RatingBuy ➝ NeutralN/A
i
Rating by E. Zhang at HC Wainwright
4/13/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $56.00N/A
i
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$29.00N/A
i
4/7/2021JPMorgan Chase & Co.UpgradeNeutralHigh
i
4/7/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $56.00High
i
4/7/2021Raymond JamesReiterated RatingSellHigh
i
4/7/2021MizuhoDowngradeBuy ➝ Neutral$72.00 ➝ $29.00High
i
4/7/2021HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by E. Zhang at HC Wainwright
3/31/2021Bank of AmericaUpgradeNeutral ➝ Buy$47.00High
i
3/8/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$75.00 ➝ $45.00N/A
i
3/8/2021SVB LeerinkLower Price TargetOutperform$91.00 ➝ $64.00N/A
i
3/2/2021SVB LeerinkLower Price TargetOutperform$91.00 ➝ $64.00High
i
3/2/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$75.00 ➝ $45.00High
i
2/1/2021HC WainwrightInitiated CoverageBuy$58.00Low
i
Rating by E. Zhang at HC Wainwright
11/6/2020SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $92.00Low
i
10/26/2020Raymond JamesInitiated CoverageUnderperformHigh
i
9/8/2020SVB LeerinkBoost Price TargetOutperform$84.00 ➝ $90.00Low
i
8/7/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $84.00High
i
5/11/2020MizuhoReiterated RatingBuyHigh
i
Rating by Difei Yang at Mizuho
5/8/2020SVB LeerinkLower Price TargetOutperform$85.00 ➝ $80.00Low
i
5/1/2020CowenInitiated CoverageMarket Perform$40.00High
i
4/27/2020Bank of AmericaInitiated CoverageNeutral$45.00Low
i
4/20/2020MizuhoReiterated RatingBuy$72.00High
i
Rating by Difei Yang at Mizuho
3/19/2020CitigroupLower Price TargetBuy$65.00 ➝ $51.00High
i
2/13/2020MizuhoReiterated RatingBuy$72.00High
i
11/18/2019MizuhoReiterated RatingBuy$72.00Low
i
Rating by Difei Yang at Mizuho
11/11/2019MizuhoReiterated RatingBuy ➝ Positive$65.00 ➝ $72.00High
i
Rating by Difei Yang at Mizuho
8/26/2019MizuhoReiterated RatingBuy$65.00Medium
i
Rating by Difei Yang at Mizuho
8/11/2019MizuhoReiterated RatingBuy$65.00High
i
7/2/2019William BlairReiterated RatingHoldLow
i
Rating by Andy Hsieh at William Blair
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$45.00Low
i
5/27/2019Piper Jaffray CompaniesReiterated RatingNeutral ➝ Positive$65.00 ➝ $40.00Low
i
5/10/2019William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by A. Hsieh at William Blair
5/10/2019MizuhoLower Price TargetBuy ➝ Positive$74.00 ➝ $65.00High
i
4/12/2019Piper Jaffray CompaniesInitiated CoverageNeutral$65.00High
i
2/11/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$71.00High
i
12/18/2018CitigroupUpgradeNeutral ➝ Buy$71.00Medium
i
Rating by Joel Beatty at Citigroup Inc.
12/17/2018MizuhoReiterated RatingBuy$74.00Medium
i
10/15/2018SVB LeerinkSet Price TargetOutperform ➝ Buy$82.00 ➝ $84.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
9/11/2018SVB LeerinkSet Price TargetBuy$82.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
8/8/2018CitigroupDowngradeBuy ➝ Hold$71.00High
i
8/8/2018MizuhoReiterated RatingBuy$74.00High
i
Rating by Salim Syed at Mizuho
6/19/2018MizuhoReiterated RatingPositive ➝ Buy$74.00High
i
Rating by Salim Syed at Mizuho
6/1/2018MizuhoReiterated RatingBuy$61.00Low
i
Rating by Salim Syed at Mizuho
5/15/2018MizuhoUpgradeNeutral ➝ Buy$61.00High
i
Rating by Salim Syed at Mizuho
3/29/2018MizuhoReiterated RatingHold$61.00Low
i
2/28/2018SVB LeerinkReiterated RatingOutperform$80.00 ➝ $88.00High
i
11/9/2017MizuhoReiterated RatingHold$61.00N/A
i
10/4/2017MizuhoInitiated CoverageNeutral$61.00N/A
i
9/14/2017Stifel NicolausReiterated RatingBuy$80.00Low
i
9/12/2017Jefferies Financial GroupReiterated RatingBuy$75.00Low
i
8/9/2017William BlairReiterated RatingOutperformMedium
i
Rating by A. Hsieh at William Blair
8/8/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$52.00 ➝ $82.00High
i
8/8/2017CitigroupBoost Price TargetTop Pick$48.00 ➝ $65.00High
i
8/8/2017Jefferies Financial GroupReiterated RatingPositive ➝ Buy$75.00 ➝ $75.00High
i
8/8/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$38.00 ➝ $80.00High
i
7/21/2017The Goldman Sachs GroupDowngradeBuy ➝ Neutral$31.00Medium
i
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$50.00High
i
6/26/2017CitigroupReiterated RatingBuy$48.00High
i
6/26/2017William BlairReiterated RatingOutperformMedium
i
Rating by A. Hsieh at William Blair
6/22/2017Stifel NicolausReiterated RatingBuy$32.00 ➝ $38.00Low
i
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
1/18/2017Stifel NicolausReiterated RatingPositive$33.00N/A
i
11/9/2016SVB LeerinkReiterated RatingBuy$52.00N/A
i
Rating by G. Porges at SVB Leerink LLC
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/25/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
5/10/2016Credit Suisse GroupReiterated RatingBuy$38.00N/A
i
Rating by Initiated, Yesterday Hold at Credit Suisse Group AG
(Data available from 4/22/2016 forward)
FibroGen logo
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $21.12
$20.51
$21.65

50 Day Range

MA: $29.60
$18.57
$35.68

52 Week Range

Now: $21.12
$18.12
$57.21

Volume

1,387,760 shs

Average Volume

1,488,074 shs

Market Capitalization

$1.94 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of FibroGen?

The following Wall Street analysts have issued research reports on FibroGen in the last year: Bank of America Co., Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Raymond James, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for FGEN.

What is the current price target for FibroGen?

6 Wall Street analysts have set twelve-month price targets for FibroGen in the last year. Their average twelve-month price target is $45.83, suggesting a possible upside of 117.0%. HC Wainwright has the highest price target set, predicting FGEN will reach $58.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $29.00 for FibroGen in the next year.
View the latest price targets for FGEN.

What is the current consensus analyst rating for FibroGen?

FibroGen currently has 1 sell rating, 5 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FGEN, but not buy more shares or sell existing shares.
View the latest ratings for FGEN.

What other companies compete with FibroGen?

Other companies that are similar to FibroGen include Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, Ascendis Pharma A/S, GW Pharmaceuticals, Evotec, Ionis Pharmaceuticals, TG Therapeutics, Perrigo, Sarepta Therapeutics, Allakos, Blueprint Medicines, Galapagos, Schrödinger, Biohaven Pharmaceutical and Sage Therapeutics.

How do I contact FibroGen's investor relations team?

FibroGen's physical mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is 415-978-1200 and its investor relations email address is [email protected] The official website for FibroGen is www.fibrogen.com.